Abstracts tagged "WNT Signaling and rheumatoid arthritis (RA)"

Abstract Number: 2506 • 2016 ACR/ARHP Annual Meeting
Seropositivity Predicts Bone Biomarker Change in an Inception Cohort of Rheumatoid Arthritis Patients Treated-to-Target with Combination Conventional DMARD Therapy
Mihir D. Wechalekar^1,2, Susan Lester³, Sunil Nagpal⁴, Jessica Peters⁵, Anuk Das⁶, Pravin Hissaria^7,8, Tania Crotti⁹, Llew Spargo¹⁰, Jennifer G Walker^1,2,10, Malcolm D. Smith¹ and Susanna M Proudman^9,10, ¹Flinders University, Adelaide, Australia, ²Rheumatology Unit, Repatriation General Hospital, Adelaide, Australia, ³Rheumatology, Queen Elizabeth Hospital, Woodville South, Australia, ⁴Immunology, Janssen Research & Development, Spring House, PA, ⁵Janssen Research & Development, Spring House, PA, ⁶Janssen R&D, Berwyn, PA, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Immunology, SA Pathology, Adelaide, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: There are limited data regarding the role of and response to treatment, of bone biomarkers in early rheumatoid arthritis (RA) treated with conventional DMARDs.…
Abstract Number: 2562 • 2015 ACR/ARHP Annual Meeting
The Inhibition of Wnt/Beta-Catenin Signaling Pathway Via Paricalcitol and Pyrvinium Ameliorates Experimental Arthritis
Suleyman Serdar Koca¹, Servet Yolbas², Ahmet Yildirim², Ahmet Tektemur³, Zulfinaz Betul Celik³, Ebru Etem Onalan³, Ibrahim Hanifi Ozercan⁴ and Mustafa Akin⁴, ¹İnternal Medicine Division of Rheumatology, Firat University, Faculty of Medicine, Elazig, Turkey, ²Rheumatology, Department of Rheumatology, Firat University, Elazig, Turkey, ³Department of Medical Biology Faculty of Medicine, Firat University, Elazig, Turkey, ⁴Department of Pathology, Faculty of Medicine, Firat University, Elazig, Turkey
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disorder, the progression of which leads to the destruction of cartilage and bone. Fibroblast-like synoviocytes (FLS) display…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].